drugset / Trial / NCT07140328
Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the safety and efficacy of the HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension compared with the placebo in the treatment of Chinese patients with COPD.
Timeline
- Start
- 2025-04-24
- Primary completion
- 2025-07-10
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HSK39004 | Unknown | 0.75 mg | Inhaled |
| Subject | HSK39004 | Unknown | 1.5 mg | Inhaled |
| Subject | HSK39004 | Unknown | 3 mg | Inhaled |